An increase in postprandial insulin ( @pmol/L * min ) , postprandial intact proinsulin ( @pmol/L * min ) , postprandial glucagon ( @pg/mL * min ) and postprandial PAI-@ levels ( @ng/mL * min ) could be observed during treatment with glimepiride , whereas treatment with linagliptin was associated with a decrease in postprandial insulin ( -@ pmol/L * min ) , intact proinsulin ( -@ pmol/L * min ) , postprandial glucagon ( -@ pg/mL * min ) and PAI-@ levels ( -@ ng/mL * min ) .